Evidence map›Paper›PMID 27677792›Full record

ArticlemBio2016

Chlamydial Protease-Like Activity Factor and Type III Secreted Effectors Cooperate in Inhibition of p65 Nuclear Translocation.

Michael John Patton, Stuart McCorrister, Chris Grant, Garrett Westmacott, Robert Fariss, Pingzhao Hu, Kaiqiong Zhao, Mary Blake, Bill Whitmire, Chunfu Yang and 2 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 26 citations in OpenAlex.

  1. RNF213-dependent lytic destruction ofProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
  3. Asiatic Acid AttenuatesInternational journal of molecular sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. mBio · 2024
    Article
  8. Review
  9. Review
  10. Frontiers in cellular and infection microbiology · 2023
    Article
  11. Review
  12. Bioprospecting by Phage Display of Mimetic Peptides ofInfection and drug resistance · 2022
    Article
  13. Article
  14. Article
  15. The multiple functions of the numerousMicrobial cell (Graz, Austria) · 2019
    Review
  16. Article
  17. Article
  18. The Loss of Expression of a Single Type 3 Effector (CT622) Strongly ReducesFrontiers in cellular and infection microbiology · 2018
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Michael John PattonLaboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Stuart McCorristerNational Microbiology Laboratories, Winnipeg, Manitoba, Canada.
Chris GrantNational Microbiology Laboratories, Winnipeg, Manitoba, Canada.
Garrett WestmacottNational Microbiology Laboratories, Winnipeg, Manitoba, Canada.
Robert FarissNational Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Pingzhao HuDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Canada.
Kaiqiong ZhaoDepartment of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Canada.
Mary BlakeNational Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Bill WhitmireLaboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Chunfu YangLaboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Harlan D CaldwellLaboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA hcaldwell@niaid.nih.gov Grant.McClarty@umanitoba.ca.
Grant McClartyNational Microbiology Laboratories, Winnipeg, Manitoba, Canada hcaldwell@niaid.nih.gov Grant.McClarty@umanitoba.ca.
National Institutes of Health Clinical Center · USUniversity of Manitoba · CANational Institute of Arthritis and Musculoskeletal and Skin Diseases · USNational Institutes of Health · US

Funding

Pathogensis of Chlamydial InfectionZIAAI000845 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CALDWELL, HARLAN D · 2009 to 2022
$14.8M
Imaging Core UnitZICEY000459 · NEI · NATIONAL EYE INSTITUTE · PI FARISS, ROBERT · 2009 to 2025
$13.1M
6 · The paper itself

Abstract

The chlamydial protease-like activity factor (CPAF) is hypothesized to be an important secreted virulence factor; however, challenges in denaturing its proteolytic activity have hampered attempts to identify its legitimate targets. Here, we use a genetic and proteomic approach to identify authentic CPAF targets. Human epithelial cells infected with CPAF-sufficient and CPAF-deficient chlamydiae were lysed using known CPAF-denaturing conditions. Their protein profiles were analyzed using isobaric mass tags and liquid chromatography-tandem mass spectrometry. Comparative analysis of CPAF-sufficient and CPAF-deficient infections identified a limited number of CPAF host and chlamydial protein targets. Host targets were primarily interferon-stimulated gene products, whereas chlamydial targets were type III secreted proteins. We provide evidence supporting a cooperative role for CPAF and type III secreted effectors in blocking NF-κB p65 nuclear translocation, resulting in decreased beta interferon and proinflammatory cytokine synthesis. Genetic complementation of null organisms with CPAF restored p65 nuclear translocation inhibition and proteolysis of chlamydial type III secreted effector proteins (T3SEs). We propose that CPAF and T3SEs cooperate in the inhibition of host innate immunity. IMPORTANCE: Chlamydia trachomatis is an important human pathogen responsible for over 100 million infections each year worldwide. Its success as an intracellular pathogen revolves around its ability to evade host immunity. The chlamydial protease-like activity factor (CPAF) is a conserved serine protease secreted into the host cytosol of infected cells that is thought to play an important role in immune evasion. Currently, CPAF's authentic in situ target(s) and mechanism of action in immune evasion are poorly characterized. Using a CPAF-deficient strain and high-throughput proteomics, we report novel CPAF host and chlamydial targets. Host targets were primarily interferon-stimulated genes, whereas chlamydial targets were exclusively type III secreted proteins. We propose a novel mechanism for CPAF and type III secreted proteins in the evasion of host innate immune responses. These findings provide new insights into CPAF's function as a virulence factor and a better understanding of how chlamydiae evade host immunity.

Identifiers

PMID27677792
PMCPMC5040114
OpenAlexW2525644600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.